Lixiana

This page shows the latest Lixiana news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Latest news

Daiichi Sankyo to shut down German antibody unit U3

Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for
Daiichi Sankyo cuts a swathe through US workforce

The company is hoping that newer products such as novel oral anticoagulant (NOAC) Savaysa/Lixiana (edoxaban) will eventually fill the void left by Benicar, which is facing a challenging start as
Daiichi Sankyo licenses clot-busting antibody

The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).
NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

NICE has backed Daiichi Sankyo's Lixiana (edoxaban) in final guidance as a treatment for adults with deep vein thrombosis and pulmonary embolism. ... In terms of its clinical effectiveness Daiichi said Lixiana proven efficacy and a significantly better
Daiichi’s new anticoagulant recommended by NICE

NICE is recommending Daiichi Sankyo's new blood thinner Lixiana as a treatment to help patients with a heart flutter who have an increased risk of stroke. ... NICE has already recommended Lixiana for the treatment of deep vein thrombosis and pulmonary

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest Intelligence

Modern anticoagulants threaten status quo

trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Digital Account Director: Salary TBC

Senior Medical Writer: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Project Manager/ Account Manager: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Great salary and benefits

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Director, Medical Education: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....